M Health Fairview partners with the University of Minnesota’s Masonic Cancer Center, which is celebrating its 30th year as the only institution in the Twin Cities designated by the National Cancer Institute as a comprehensive cancer center. That partnership gives M Health Fairview access to more than 225 clinical trials to treat over 100 types of cancer, and 78,000-plus people have participated in clinical trials since the center earned NCI designation in 1998. M Health Fairview University of Minnesota Medical Center was ranked No. 33 in the nation for cancer care in U.S. News & World Report’s 2026-27 rankings. Its radiation oncology team develops individualized treatment plans for more than 2,500 new patients each year, and M Health Fairview is among a small number of centers nationwide to offer CAR T-cell therapy for patients whose cancer has returned or not responded to other treatments. Surgical oncologists at M Health Fairview started one of the first hyperthermic intraperitoneal chemotherapy programs in the region, and the system recently opened five new multi specialty breast cancer clinics across the Minneapolis-St. Paul metro area. In June 2026, the University of Minnesota and Fairview Health Services finalized a 10-year agreement under which Fairview is investing $1 billion in the medical center and providing $50 million annually to the medical school.
